Skip to main content

Table 2 Patients’ characteristics and their relation to tamoxifen response

From: Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients

Feature

Responders (78)

Refractory (79)

P value

Age (years)

 > 50 (81)

40 (51.3%)

41 (51.9%)

1.0

 ≤ 50 (76)

38 (48.7%)

38 (48.1%)

Menstrual status

 Pre (73)

36 (46.2%)

37 (46.8%)

1.0

 Post (84)

42 (53.8%)

42 (53.2%)

Histological grade

 II (114)

57 (73.1%)

57 (72.2%)

0.69

 III (43)

21 (26.9)

22 (27.8%)

Contraception

 Yes (31)

17 (21.8%)

14 (17.7%)

0.55

 No (126)

61 (78.2%)

65 (82.3%)

Her-2 status

 +ve (58)

31 (39.7%)

27 (34.2%)

0.51

 −ve (99)

47 (60.3%)

52 (65.8%)

ER

 +ve (108)

52 (66.7%)

56 (70.9%)

0.61

 −ve (49)

26 (33.3%)

23 (29.1%)

PR

 +ve (78)

38 (48.7%)

40 (50.6%)

1.00

 −ve (79)

40 (51.3%)

39 (49.4%)

Disease site

 Bone only (46)

31 (39.7%)

15 (18.9%)

0.005*

 Visceral (111)

47 (60.3%)

64 (81.1%)